PRNB stock forecast
Our latest prediction for Principia Biopharma, Inc.'s stock price was made on the Dec. 18, 2019 when the stock price was at 54.39$.
In the short term (2weeks), PRNB's stock price should underperform the market by -4.91%. During that period the price should oscillate between -10.00% and +7.41%.
In the medium term (3months), PRNB's stock price should underperform the market by -14.98%. During that period the price should oscillate between -29.48% and +16.40%.Get email alerts
About Principia Biopharma, Inc.
Principia Biopharma, Inc. is a biopharmaceutical company, which engages in design and development oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to purpose-design and develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline include PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 28, 2008 and is headquartered in South San Francisco, CA.
At the moment the company generates 61M USD in revenues.
On its last earning announcement, the company reported a loss of -0.64$ per share.
The book value per share is 6.66$
Three months stock forecastDec. 18, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|